(Q43448077)

23 November 2017

title

Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis (English)

1 reference

23 November 2017

Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis (English)

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

21 July 2024

0 references

G. Oster

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655127

21 July 2024

D. M. Huse

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655127

21 July 2024

M. J. Lacey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655127

21 July 2024

M. M. Regan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655127

21 July 2024

H. J. Fuchs

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655127

21 July 2024

language of work or name

English

0 references

publication date

1 May 1995

1 reference

full work available at URL

23 November 2017

http://www.theannals.com/cgi/content/abstract/29/5/459

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655127

http://journals.sagepub.com/doi/pdf/10.1177/106002809502900501

21 July 2024

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Annals of Pharmacotherapy

21 July 2024

published in

1 reference

23 November 2017

volume

29

1 reference

23 November 2017

issue

5

1 reference

23 November 2017

page(s)

459-464

1 reference

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900501

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900501

The changing epidemiology of cystic fibrosis

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease

21 July 2024

3

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

21 July 2024

5

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

21 July 2024

6

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

21 July 2024

8

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Rapid estimation of hospital charges in patients with leukemia. Validation of a multivariate prediction model

21 July 2024

10

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

American journal of hospital pharmacy

21 July 2024

12

45

2341

Chamberlain TM

1988

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

Topics in health care financing

21 July 2024

15

13

32

Baptist A.

1987

1 reference

https://api.crossref.org/works/10.1177/106002809502900501

21 July 2024

Identifiers

1 reference

23 November 2017

1 reference